Header Logo

Connection

LISA BOMGAARS to Humans

Back to Details
This is a "connection" page, showing publications LISA BOMGAARS has written about Humans.
LISA BOMGAARS
Connection Strength
0.216
Humans
  1. Antithrombotic Therapy in a Prospective Trial of a Pediatric Ventricular Assist Device. ASAIO J. 2016 Nov/Dec; 62(6):719-727.
    View in: PubMed
    Score: 0.014
  2. Response to warfarin therapy in obese pediatric patients dosed according to institutional guidelines. J Pediatr Hematol Oncol. 2014 Nov; 36(8):e487-9.
    View in: PubMed
    Score: 0.012
  3. Readmissions for warfarin-related bleeding in pediatric patients after hospital discharge. Pediatr Blood Cancer. 2013 Sep; 60(9):1503-6.
    View in: PubMed
    Score: 0.011
  4. Risk factors for elevated INR values during warfarin therapy in hospitalized pediatric patients. Pediatr Blood Cancer. 2012 Jun; 58(6):941-4.
    View in: PubMed
    Score: 0.010
  5. Development of factor V and thrombin inhibitors in children following bovine thrombin exposure during cardiac surgery: a report of three cases. Congenit Heart Dis. 2010 May-Jun; 5(3):303-8.
    View in: PubMed
    Score: 0.009
  6. Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. Pediatr Blood Cancer. 2008 Oct; 51(4):504-8.
    View in: PubMed
    Score: 0.008
  7. Low prevalence and assay discordance of "aspirin resistance" in children. Pediatr Blood Cancer. 2008 Jul; 51(1):86-92.
    View in: PubMed
    Score: 0.008
  8. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007 Oct 10; 25(29):4622-7.
    View in: PubMed
    Score: 0.007
  9. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007 May; 59(6):847-53.
    View in: PubMed
    Score: 0.007
  10. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors. Pediatr Blood Cancer. 2006 Aug; 47(2):163-8.
    View in: PubMed
    Score: 0.007
  11. A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer. 2006 Jan; 46(1):50-5.
    View in: PubMed
    Score: 0.007
  12. Pharmacogenetics and pediatric cancer. Cancer J. 2005 Jul-Aug; 11(4):314-23.
    View in: PubMed
    Score: 0.006
  13. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004 Oct 01; 22(19):3916-21.
    View in: PubMed
    Score: 0.006
  14. Dabigatran for Treatment and Secondary Prevention of Venous Thromboembolism in Pediatric Congenital Heart Disease. J Am Heart Assoc. 2024 Feb 20; 13(4):e028957.
    View in: PubMed
    Score: 0.006
  15. Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia. Blood Adv. 2022 11 22; 6(22):5908-5923.
    View in: PubMed
    Score: 0.005
  16. Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials. Thromb Haemost. 2022 Sep; 122(9):1573-1583.
    View in: PubMed
    Score: 0.005
  17. Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 12; 68(12):e29333.
    View in: PubMed
    Score: 0.005
  18. Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. J Thromb Haemost. 2021 05; 19(5):1259-1270.
    View in: PubMed
    Score: 0.005
  19. The development of camptothecin analogs in childhood cancers. Oncologist. 2001; 6(6):506-16.
    View in: PubMed
    Score: 0.005
  20. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2021 Jan; 8(1):e22-e33.
    View in: PubMed
    Score: 0.005
  21. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020 02 13; 135(7):491-504.
    View in: PubMed
    Score: 0.004
  22. The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children's Oncology Group. Clin Pharmacokinet. 2019 07; 58(7):899-910.
    View in: PubMed
    Score: 0.004
  23. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2018 09 20; 36(27):2770-2777.
    View in: PubMed
    Score: 0.004
  24. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability. J Thromb Haemost. 2017 11; 15(11):2147-2157.
    View in: PubMed
    Score: 0.004
  25. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. J Clin Oncol. 2016 09 01; 34(25):3031-8.
    View in: PubMed
    Score: 0.003
  26. Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency. Thromb Haemost. 2016 07 04; 116(1):58-68.
    View in: PubMed
    Score: 0.003
  27. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2014 Jun; 15(5):e198-205.
    View in: PubMed
    Score: 0.003
  28. Anticoagulation therapy trends in children supported by ventricular assist devices: a multi-institutional study. ASAIO J. 2014 Mar-Apr; 60(2):211-5.
    View in: PubMed
    Score: 0.003
  29. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin. J Pediatr. 2013 Feb; 162(2):293-6.
    View in: PubMed
    Score: 0.003
  30. Prospective trial of a pediatric ventricular assist device. N Engl J Med. 2012 Aug 09; 367(6):532-41.
    View in: PubMed
    Score: 0.003
  31. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2012 Mar; 58(3):395-8.
    View in: PubMed
    Score: 0.002
  32. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011 Jul 07; 118(1):28-36.
    View in: PubMed
    Score: 0.002
  33. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010 Jun; 33(6):1294-6.
    View in: PubMed
    Score: 0.002
  34. Pediatric warfarin practice and pharmacogenetic testing. Thromb Res. 2010 Aug; 126(2):e144-6.
    View in: PubMed
    Score: 0.002
  35. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009 Sep 10; 27(26):4392-7.
    View in: PubMed
    Score: 0.002
  36. Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. Antimicrob Agents Chemother. 2009 May; 53(5):1912-20.
    View in: PubMed
    Score: 0.002
  37. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol. 2009 Jul; 64(2):243-51.
    View in: PubMed
    Score: 0.002
  38. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group. Cancer Chemother Pharmacol. 2008 Nov; 62(6):1027-37.
    View in: PubMed
    Score: 0.002
  39. Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. J Pediatr. 2008 Jan; 152(1):101-5.
    View in: PubMed
    Score: 0.002
  40. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol. 2008 Jul; 62(2):355-61.
    View in: PubMed
    Score: 0.002
  41. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 01; 13(5):1516-22.
    View in: PubMed
    Score: 0.002
  42. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther. 2007 Apr; 81(4):510-6.
    View in: PubMed
    Score: 0.002
  43. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006 Apr 20; 24(12):1917-23.
    View in: PubMed
    Score: 0.002
  44. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res. 2006 Mar 01; 12(5):1540-6.
    View in: PubMed
    Score: 0.002
  45. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes. 2005 Apr; 54(4):1100-7.
    View in: PubMed
    Score: 0.002
  46. Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol. 2004 Nov 01; 22(21):4394-400.
    View in: PubMed
    Score: 0.002
  47. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia. 2002 May; 16(5):920-7.
    View in: PubMed
    Score: 0.001
  48. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001 Apr 15; 19(8):2293-301.
    View in: PubMed
    Score: 0.001
  49. Lymphoid malignancies following Kawasaki disease. Am J Hematol. 1995 Dec; 50(4):299-300.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.